Stuart graduated from the University of Leeds in the UK with a First Class Honours degree in Pharmacology and was awarded the Pfizer Prize for his undergraduate research. For his doctoral studies, he received the Ackroyd, Brotherton, and Brown Scholarship at the University of Leeds.
He was later awarded a Howard Hughes Medical Institute Fellowship to train with Professor Robert Lefkowitz (2012 Nobel Laureate in Chemistry) at Duke University. Following this postdoctoral fellowship, Stuart was recruited as Principal Investigator of the Receptor Biology Section at the Medical Research Council (MRC) Human Reproductive Sciences Unit at the University of Edinburgh. During his time at the MRC, he developed novel prostate cancer therapeutics based on his research into G protein-coupled receptor (GPCR) pluridimensional signaling.
To further expand his biomedical expertise, Stuart accepted the position of Head of the Receptor Pharmacology Unit at the National Institutes of Health – National Institute on Aging at the Johns Hopkins University Medical Center. While at the NIH, he received the prestigious NIH “Bench-to-Bedside” Translational Research Grant Award, one of the few awards available within the intramural NIH program.
After starting a family and returning to Europe, Stuart continued his scientific work, receiving the highly regarded Odysseus Type I Program Grant. He went on to serve as Adjunct Director of the VIB Center for Molecular Neurology and Vice-Chair of the Department of Biomedical Sciences at the University of Antwerp.
Stuart’s current research, conducted in his Receptor Biology Lab, focuses on the development of novel GPCR-based anti-aging therapeutics. This work is now forming the foundation of a new technology-based startup dedicated to screening and developing innovative longevity and disease-modulating compounds.